Company profile: Eligo Bioscience
1.1 - Company Overview
Company description
- Provider of CRISPR/Cas and engineered phage capsid-based antimicrobials and microbiome editing technologies to control bacterial ecosystems in humans and animals. Solutions include the GEM platform for in vivo gene editing, SSAM sequence-specific antimicrobials, FAME for therapeutic gene addition, and capabilities for gene removal, modification, and addition to eradicate resistant pathogens and modulate disease mechanisms.
Products and services
- SSAM Technology: Sequence-specific anti-microbials employing CRISPR systems to kill harmful, resistant, or virulent bacteria while sparing beneficial microbiota by targeting specific sequences within pathogens
- GEM Platform: In vivo gene-editing system for the microbiome enabling precise modification of bacterial genes to address diseases, including gene removal, gene addition, and sequence modification in target species
- FAME Technology: Therapeutic-gene platform introducing genes into microbial populations to modulate disease mechanisms, delivering therapeutic genes to target bacterial species within human or animal microbiomes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eligo Bioscience
NXT-Dx
HQ: Belgium
Website
- Description: Provider of epigenetics services from a private company led by an experienced team combining skills in epigenetics, transcriptomics, proteomics, and bioinformatics research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NXT-Dx company profile →
SNIPR Biome
HQ: Denmark
Website
- Description: Provider of CRISPR-based microbial gene therapies that selectively target and eliminate hazardous bacteria without harming beneficial microbes; gut-directed gene therapy via engineered bacteria; CRISPR-Guided Vectors (CGV) for rapid, precise bacterial killing; platforms for in situ therapeutic protein and peptide production; backed by an extensive patent portfolio and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SNIPR Biome company profile →
Nightingale Health
HQ: Finland
Website
- Description: Provider of pioneering blood-testing services and proprietary blood analysis technology that delivers deep health insights, identifies disease risks from a single sample, and measures the effects of lifestyle interventions. Offers Nightingale Pro data platform for detecting population-level disease risks and preventative health needs, and biomarker analysis services for researchers across blood, urine, and dried blood spot samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nightingale Health company profile →
Health in Code
HQ: Spain
Website
- Description: Provider of genetic diagnosis and testing services for inherited diseases, with expertise in inherited cardiovascular conditions. Services include full NGS testing from DNA reception to specialized clinical reports, in-house sequencing kits with bioinformatics and variant database, variant interpretation per guidelines, multidisciplinary clinical genetic reports, specialist genetic counseling, and proteomics as a certified Olink Explore service provider.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Health in Code company profile →
Strata Oncology
HQ: United States
Website
- Description: Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strata Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eligo Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eligo Bioscience
2.2 - Growth funds investing in similar companies to Eligo Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eligo Bioscience
4.2 - Public trading comparable groups for Eligo Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →